In the first three months of the year, Danish pharmaceutical company Novo Nordisk's net result increased steadily, while its top line has landed at the same level as last year, according to the firm's interim report for Q1 which was published Monday morning.
The report also reveals that the firm plans to upgrade its outlook for 2021.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Regulatory affairs life cycle specialist 
Formulation Specialist, Oral Formulation Research - Novo Nordisk 
(Senior) Regulatory Science Specialist - IWA Consulting 
Clinical Trial Manager - Genmab 
Radiochemist in CMC Development - Y-mAbs Therapeutics 
Employee for regulatory department 
Principal Biostatistician - ALK 
Senior Clinical Development Scientist/Physician - Lundbeck 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen 
eTMF Manager - Klifo